Home›Trial›NCT06906341
🔬NCT06906341Phase 2RECRUITING

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Study Summary

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal NeoplasmsEndometrial Cancer
Interventions / Drugs
Relacorilant 150 mg once daily (QD)Nab-paclitaxel 80 mg/m^2Bevacizumab 10 mg/kg
View on ClinicalTrials.gov ↗
Sponsor
CORT
Corcept Therapeutics
Endocrinology
C59/100
Study Details
Enrollment270 participants
Primary Completion—
Lead SponsorCorcept Therapeutics
Data Retrieved2026-04-11 04:10:22.666713+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.